Member Info for TRENCH123

The £137k grant covers the two-year study through to October 2025. Income will be credited to each accounting period on a pro-rata basis depending on the work completed in that period. It is likely that the initial scoping out work would have started before 31st December 2023 but I would expect that the amount to be credited for this work would be relatively small

I do not believe there will be much grant income in the half year to 31st December 2023. Time spent on the new Blackpool Victoria Hospital study would be minimal by that date and the old Portsmouth Hospital work was complete by early 2023

Maybe I am missing something ?

I posted this early January :

A PYC tweet issued last week included 'We can’t wait to share with you all the exciting developments we have planned for the year ahead'. Interestingly, Valirx issued a similarly worded tweet including 'we're looking forward to showing you what we have planned for an exciting year ahead'

Probably coincidence or perhaps they use the same script writer. Could it be there is some form of closer working relationship between the two planned ?

I note that there have been no exciting developments this calendar year on either PYC or VAL. Clarification will be needed on the tweet at Physiomics IMC presentation later this month if nothing substantial announced by then

KingH I totally agree with your sentiment

People are holding the stock they have whilst awaiting the next news which is a reasonable thing to do

Next trigger could be the half year results due next week. Following poor figures last year JM recently commented that PYC were 'on track' to turning things around. What that translates into remains to be seen

There will undoubtedly be people sitting on the sidelines waiting to jump in on decent news. It is not the way I invest, but it is clearly the way many people play AIM these days

Closing off contracts does clearly take time. The initial University of Sheffield contract was May 2023 with the comment that 'a longer-term collaboration is currently under discussion'. Even so, the second contract was only announced just over a week ago

The major shareholder listing on the PYC website has been updated today

It shows Gary Marshall with 3.69 % (he was showing on the August 2023 update) and Ben Ryden with 3.21% (he was not on the August 2023 update. but may have been on earlier updates)

A song for all Valirx shareholders

https://www.youtube.com/watch?v=xyHoohNyYkw

I don't see any reason why the BOD should look like fools. They can only tell you how they see it at the time of the presentation. I am sure they are trying their utmost to get the deals over the line, unfortunately the proposal is put to the client and the timing of any final decision is outside their control. Hence, the reason why the contracts come through in fits and starts. I agree that it can be frustrating for investors (and no doubt directors too !!). It gives the impression that little is happening, but clearly a lot of hard work is going on in the background

Laura, I also think Peter Sargent is a good appointment and he will make his mark in 2024

I noted the delayed 5 million @4.60 sell and corresponding 5 million @4.65 buy from yesterday now showing

This could be linked to the Sanderson Capital major holdings notification RNS of 12th February (17th January threshold crossed) also involving 5m shares. Have Sanderson acquired the 5m shares on behalf of a client and this is the onward transfer transaction ?

Sanderson must have paid a minimum 5p per share. If someone is forking out £230k then they must have confidence in the future of Valirx

It was Tabula Rasa's decision to sell Dosemerx which rather stalled any momentum. Dosemerx seems more focused under its new owners and It could still be a route to commercialisation over the next couple of years for PYC

I am OK with shareholder dialogue. The information given at IMC presentations is I suspect as comprehensive as it can be, given that they also have to balance this with client confidentiality. Contrary to some other people, I find the tweets useful in that they help you keep abreast of what is happening both from a company and industry perspective

The newsletters disappointingly only contain what is already in the public domain, but are probably targeted more at existing/potential clients than investors/potential investors

I agree that the focus on market value has never appeared a priority with PYC and it is a bit frustrating. When you are in a market which deals with cancer treatments it is perhaps somewhat unprofessional/unethical to be talking about making money. I think the company philosophy is that if their business plan (as per latest IMC presentation) is successful then the share price will take care of itself. JM mentions that he is 'confident' and 'optimistic'. Lets see how it pans out though

You need to watch the Investor Meet Company presentations wherein detailed explanations are to be found (1.Merck 2. Client confidentiality)

I am not sure it should be classified as a battle. It is not impossible that Suzy could still turn this around in the limited time available to her. I hope she does. Nobody really knows what is happening behind the scenes

I am a bit disappointed that Adam has felt unable to comment on here subsequent to finishing on the Valirx SAB. His observations would be very welcome

Maybe he is too busy with his own company and also Aptamer. He joined Aptamer as an NED on 31st July 2023 when the share price was 2.00p - it is now 0.625p !!

Jim mentioned in the November 2023 IMC meeting that the primary reason for moving was the 'flexible working environment' at Bee House. PYC employees only work in the office part of the time and to pay only for the time occupied would result in cost savings and made sense

Nice to see some praise for Suzy. Lets hope the good news continues

Some people were a little negative about PYC's move out of central Oxford. Looks like Milton Park is an equally dynamic environment with maybe the possibility of useful connections being made

Interesting articles on other Cancer-related companies operating from Milton Park

https://www.miltonpark.co.uk/occupier-news/cancer-and-vaccine-developments/

https://www.miltonpark.co.uk/business/milton-park-companies-secure-over-7-of-uks-life-sciences-investment-2/

Tweet from PYC on 5th January : 'We can’t wait to share with you all the exciting developments we have planned for the year ahead .....' 'Here's to a year full of growth!'

One assumes we will be enlightened before too long ?